1054 -FINAL VERSION 30th Dec 2007 Clinical and biochemical improvement in Type 2 diabetic parameters in type 2 diabetic men with symptomatic testosterone deficiency syndrome (TDS). A double blind, placebo controlled study of depot testosterone undecanoate (NEBIDO) versus placebo in a primary care setting.

Trial Profile

1054 -FINAL VERSION 30th Dec 2007 Clinical and biochemical improvement in Type 2 diabetic parameters in type 2 diabetic men with symptomatic testosterone deficiency syndrome (TDS). A double blind, placebo controlled study of depot testosterone undecanoate (NEBIDO) versus placebo in a primary care setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms BLAST; BLT-T2D
  • Most Recent Events

    • 01 Nov 2016 Results assessing changes in sexual function score within group and between groups, published in the BJU International.
    • 01 Sep 2013 Status changed from recruiting to completed as estimated from the results published in Urology.
    • 01 Sep 2013 Primary endpoint 'International-Index-of-Erectile-Function' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top